Hou et al. (103) demonstrated synergistic inhibition of tumor growth in a mouse model of postmenopausal estrogen receptor positive (ER+) breast cancer following treatment with BMS-754807 plus letrozole or tamoxifen. Here, ESR1 is linked to breast cancer.